| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10029117 | International Journal of Infectious Diseases | 2005 | 6 Pages |
Abstract
A majority of the MDR-TB patients in Iran can be cured with the use of appropriate treatment regimens. An even greater success could be achieved by providing more second-line drugs.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Seyed Mehdi Mirsaeidi, Payam Tabarsi, Kaveh Khoshnood, Majid Valiollah Pooramiri, Ali Rowhani-Rahbar, Seyed Davood Mansoori, Heydar Masjedi, Soheyla Zahirifard, Foroozan Mohammadi, Parisa Farnia, Mohammad Reza Masjedi, Ali Akbar Velayati,